Literature DB >> 33382745

Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey.

Jingbo Yu1, Dilan Paranagama1, Shreekant Parasuraman1.   

Abstract

BACKGROUND: Recruitment of individuals with rare diseases for studies of real-world patient-reported outcomes is limited by small base populations. Myeloproliferative neoplasms (MPNs) are a group of rare, chronic, hematologic malignancies. In this study, recruitment strategies and geographic representativeness from the Living with MPNs survey are reported.
METHODS: The Living with MPNs online cross-sectional survey was conducted between April and November 2016. Individuals 18 to 70 years of age living in the United States and diagnosed with an MPN were eligible to participate. Recruitment approaches included direct contact via emails and postcards; posts on MPN-focused social media and patient advocacy websites; postcard mailings to doctors' offices; and advertisements on medical websites, Google, and Facebook. Geographic representativeness was assessed based on the number of survey respondents living in each state or the District of Columbia and by the number of survey respondents per 10 million residents.
RESULTS: A total of 904 respondents with MPNs completed the survey. The recruitment method yielding the greatest number of respondents was advertisements on MPN-focused social media (47.6% of respondents), followed by emails (35.1%) and postcards (13.9%) sent through MPN advocacy groups. Home state information was provided by 775 respondents from 46 states (range of respondents per state, 1-89). The number of respondents per 10 million residents in the 46 states with respondents ranged from 12.1 to 52.7.
CONCLUSIONS: Recruitment using social media and communications through patient groups and advocacy organizations are effective in obtaining geographically representative samples of individuals with MPNs in the United States. These approaches may also be effective in other rare diseases.

Entities:  

Year:  2020        PMID: 33382745      PMCID: PMC7774910          DOI: 10.1371/journal.pone.0243562

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  20 in total

1.  Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.

Authors:  Amye J Tevaarwerk; Ju-Whei Lee; Abigail Terhaar; Mary E Sesto; Mary Lou Smith; Charles S Cleeland; Michael J Fisch
Journal:  Cancer       Date:  2015-12-21       Impact factor: 6.860

2.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Authors:  Malin Hultcrantz; Sigurdur Yngvi Kristinsson; Therese M-L Andersson; Ola Landgren; Sandra Eloranta; Asa Rangert Derolf; Paul W Dickman; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

3.  A Diversified Recruitment Approach Incorporating Social Media Leads to Research Participation Among Young Adult-Aged Female Cancer Survivors.

Authors:  Jessica R Gorman; Samantha C Roberts; Sally A Dominick; Vanessa L Malcarne; Andrew C Dietz; H Irene Su
Journal:  J Adolesc Young Adult Oncol       Date:  2014-06-01       Impact factor: 2.223

Review 4.  Can we use social media to support content validity of patient-reported outcome instruments in medical product development?

Authors:  Margaret Rothman; Ari Gnanaskathy; Paul Wicks; Elektra J Papadopoulos
Journal:  Value Health       Date:  2015-01       Impact factor: 5.725

5.  The Use of Social Media to Recruit Participants With Rare Conditions: Lynch Syndrome as an Example.

Authors:  Allison M Burton-Chase; Wendy M Parker; Kelsey Hennig; Faith Sisson; Linda L Bruzzone
Journal:  JMIR Res Protoc       Date:  2017-01-23

6.  Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.

Authors:  Ruben Mesa; Carole B Miller; Maureen Thyne; James Mangan; Sara Goldberger; Salman Fazal; Xiaomei Ma; Wendy Wilson; Dilan C Paranagama; David G Dubinski; John Boyle; John O Mascarenhas
Journal:  BMC Cancer       Date:  2016-02-27       Impact factor: 4.430

7.  Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.

Authors:  Jingbo Yu; Shreekant Parasuraman; Dilan Paranagama; Andrew Bai; Ahmad Naim; David Dubinski; Ruben Mesa
Journal:  BMC Cancer       Date:  2018-04-13       Impact factor: 4.430

Review 8.  Patient reported outcome measures in rare diseases: a narrative review.

Authors:  Anita Slade; Fatima Isa; Derek Kyte; Tanya Pankhurst; Larissa Kerecuk; James Ferguson; Graham Lipkin; Melanie Calvert
Journal:  Orphanet J Rare Dis       Date:  2018-04-23       Impact factor: 4.123

9.  A comparison of three methods to generate a conceptual understanding of a disease based on the patients' perspective.

Authors:  Louise Humphrey; Thomas Willgoss; Andrew Trigg; Stephanie Meysner; Mary Kane; Sally Dickinson; Helen Kitchen
Journal:  J Patient Rep Outcomes       Date:  2017-12-19

10.  Reasons for not initiating osteoporosis therapy among a managed care population.

Authors:  Jingbo Yu; Susan K Brenneman; Vasilisa Sazonov; Ankita Modi
Journal:  Patient Prefer Adherence       Date:  2015-06-19       Impact factor: 2.711

View more
  2 in total

1.  Comparison of Web-Based Advertising and a Social Media Platform as Recruitment Tools for Underserved and Hard-to-Reach Populations in Rheumatology Clinical Research.

Authors:  Vladislav Tsaltskan; Katherine Nguyen; Christina Eaglin; V Michael Holers; Kevin D Deane; Gary S Firestein
Journal:  ACR Open Rheumatol       Date:  2022-05-10

2.  General Practice and Digital Methods to Recruit Stroke Survivors to a Clinical Mobility Study: Comparative Analysis.

Authors:  Katja Reuter; Chang Liu; NamQuyen Le; Praveen Angyan; James M Finley
Journal:  J Med Internet Res       Date:  2021-10-13       Impact factor: 5.428

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.